Overview

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Status:
Recruiting

Trial end date:
2037-11-16

Target enrollment:

Participant gender:

Summary

The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborators:

Mustang Bio
National Cancer Institute (NCI)

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine